Anti-diabetic and toxic effects of vanadium compounds

Molecular and Cellular Biochemistry

Volumn 206, Issue 1-2, 2000, Pages 177-182

  Srivastava, Ashok K ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; STREPTOZOCIN; TRACE ELEMENT; VANADATE SODIUM; VANADIUM DERIVATIVE; VANADYL SULFATE;

ARTICLE; DRUG EFFECT; GASTROINTESTINAL DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIVER TOXICITY; MOLECULAR MIMICRY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STREPTOZOCIN DIABETES; WEIGHT GAIN;

ANIMALIA; RODENTIA;

EID: 0034013822     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1007075204494     Document Type: Article

References (57)

1. Chasteen ND: The biochemistry of vanadium. In: Structure and Bonding. Springer Verlag, Berlin, Heidelberg, 1983, pp 105-138
2. Srivastava AK: Potential use of vanadium compounds in the treatment of diabetes mellitus. Exp Opin Invest Drugs 4: 525-536, 1995
3. Lyonnet B, Martz M, Martin E: L'emploi thérapeutique des dérivés du vanadium. La Presse Médicale 32: 191-192, 1899
4. Tolman EL, Barris E, Bums M, Pansini A, Partridge R: Effects of vanadium on glucose metabolism in vitro. Life Sci 25: 1159-1164, 1979
5. Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39: 1-5, 1990
6. Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated glucose and depressed cardiac performance of diabetic rats. Science 227: 1474-1477, 1985
7. Brichard SM, Lederer J, Henquin J-C: The insulin-like properties of vanadium: A curiosity or a perspective for the treatment of diabetes? Diabetes Metab 17: 435-440, 1991
8. Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 188: 73-80, 1998
9. McNeill JH, Yuen VG, Hoveyda HR, Orvig C: Bis(maltolato)-oxovanadium (IV) is a potent insulin mimic. J Med Chem 35: 1489-1491, 1992
10. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS, Shaver A: Peroxovanadium compounds: A new class of potent phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604, 1994
11. Shisheva A, Ikonomov O, Shechter Y: The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats. Endocrinology 134: 507-510, 1994
12. Karasik A, Hattori M: Use of animal models in the study of diabetes. In: C.R. Kahn, G.C. Weir (eds). Jolin's Diabetes Mellitus. Lea and Febiger, Philadelphia, 1994, pp 317-350
13. Meyerovitch J, Farfel Z, Sack J, Shechter Y: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J Biol Chem 262: 6658-6662, 1987
14. Gil J, Miralpeix M, Carreras J, Bartrons R: Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats. J Biol Chem 263: 1868-1871, 1988
15. Brichard SM, Okitolonda W, Henquin JC: Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123: 2048-2053, 1988
16. Blondel O, Bailbe D, Portha B: In vivo insulin resistance in streptozotocindiabetic rats - evidence for reversal following oral vanadate treatment. Diabetologia 32: 185-190, 1989
17. Bendayan M, Gingras D: Effects of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocindiabetic rats. Diabetologia 32: 561-567, 1989
18. Ramanadham, S, Mongold J-J, Brownsey RW, Cros GH, McNeill JH: Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am J Physiol 257: H904-H911, 1989
19. Bollen M, Miralpeix M, Ventura F, Toth B, Bartrons R, Stalmans W: Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase. Biochem J 267: 269-271, 1990
20. Strout HV, Vicario PP, Biswas C, Superstein R, Brady EJ, Pilch PF, Berger J: Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin responsive glucose transporter in skeletal muscle. Endocrinology 126: 2728-2732, 1990
21. Sekar N, Kanthasamy A, William S, Subramanian S, Govindasamy S: Insulin actions of vanadate in diabetic rats. Pharmacol Res 22: 207-217, 1989
22. Sakurai H, Tsuchiya K, Nukatsuka M, Sofue M, Kawada J: Insulin-like effects of vanadyl ion in streptozotocin-induced diabetic rats. J Endocrinol 126: 451-459, 1990
23. Pugazhenthi S, Khandelwal RL: Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 39: 821-827, 1990
24. Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84: 892-899, 1989
25. Venkatesan N, Avidan A, Davidson MB: Antidiabetic action of vanadyl in rats independent of in vivo insulin-receptor kinase activity. Diabetes 40: 492-498, 1991
26. Saxena AK, Srivastava P, Bacquer NZ: Effects of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and -independent tissues of diabetic rats. Eur J Pharmacol 216: 123-126, 1992
27. +)-dependent glucose transport in rat small intestine. Diabetes 42: 1126-1132, 1993
28. Valera A, Rodriguez-Gil JE, Bosch F: Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. J Clin Invest 92: 4-11, 1993
29. Malabu. UH, Dryden S, McCarthy HD, Kilpatrick A, Williams G: Effects of chronic vanadate administration in the STZ-induced diabetic rat. The antihyperglycemic action of vanadate is attributable entirely to its suppression of feeding. Diabetes 43: 9-15, 1994
30. Pederson RA, Ramanadham S, Buchan AMJ, McNeill JH: Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes 38: 1390-1395, 1989
31. Yuen VG, Orvig G, McNeill JH: Glucose lowering effect of a new organic vanadium complex, bis(maltolato)oxovanadium (IV). Can J Physiol Pharmacol 71: 263-269, 1993
32. Yuen VG, Orvig C, Thompson KH, McNeill JH: Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium (VI). Can J Physiol Pharmacol 71: 270-276, 1993
33. Reul BA, Amin SS, Buchet JP, Ongemba L-N, Crans DC, Brichard SM: Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Br J Pharmacol 126: 4674-4677, 1999
34. Yale J-F, Lachance D, Bevan AP, Vigeant C, Shaver A, Posner BI: Hypoglycemic effects of peroxovanadium compounds in Sprague-Dawley and diabetic BB rats. Diabetes 44: 1274-1279, 1995
35. Brichard SM, Pottier AM, Henquin JC: Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology 125: 2510-2516, 1989
36. Pugazhenthi S, Angel JF, Khandelwal RL: Long-term effects of vanadate treatment on glycogen metabolizing and lipogenic enzymes of liver in genetically diabetic (db/db) mice. Metabolism 40: 941-946, 1991
37. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 87: 1286-1294, 1991
38. Brichard SM, Bailey CJ, Henquin J-C: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39: 1326-1332, 1990
39. Yuen VG, Pederson RA, Dai S, Orvig C, McNeill JH: Effects of low and high dose administration of bis(maltolato)oxovanadium (IV) on fa/fa Zucker rats. Can J Physiol Pharmacol 74: 1001-1009, 1996
40. Goldfine AB, Simonson DC, Folli F, Patti M-E, Kahn CR: In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus. Mol Cell Biochem 153: 217-231, 1995
41. Cohen N, Halberstam M, Shlimovich P, Chang O, Shamoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95: 2501-2509, 1995
42. Boden G, Chen X, Ruiz J, van Rossum DV, Turco S: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 45: 1130-1135, 1996
43. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45: 659-666, 1996
44. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL: Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation. Mol Cell Biochem 153: 233-240, 1995
45. Domingo JL, Gomez M, Llobet JM, Corbella J, Keen CL: Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology 66: 279-287, 1991
46. Oster MH, Llobet JM, Domingo JL, German JB, Keen CL: Vanadium treatment of diabetic Sprague-Dawley rats results in tissue vanadium accumulation and prooxidant effects. Toxicology 83: 115-130, 1993
47. Nechay BR, Nanninga LB, Nechay PSE, Post RL, Grantham JJ, Macara IG, Kubena LF, Phillips TD, Nielsen FH: Role of vanadium in biology. Fed Proc 45: 123-132, 1986
48. Al-Bayati MA, Giri SN, Raah OG: Time and dose response study of the effects of vanadate in rats: Changes in blood cells, serum enzymes, protein, cholesterol, glucose, calcium and inorganic phosphate. J Environ Pathol Toxicol Oncol 10: 206-213, 1990
49. Bishayee A, Cecchin F: Time course effects of vanadium supplement on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol Trace Element Res 48: 275-285, 1995
50. Mongold JJ, Cros GH, Vian L, Tep A, Ramanadham S, Siou G, Diaz J, McNeill JH, Serrano JJ: Toxicological aspects of vanadyl sulphate on diabetic rats: Effects on vanadium levels and pancreatic b-cell morphology. Pharmacol Toxicol 67: 192-198, 1990
51. Sanchez MT, Domingo JL: Effects of vanadium on activity and learning in rats. Physiol Behav 63: 345-350, 1998
52. Wang H, Scott RE: Unique and selective mitogenic effects of vanadate on SV40-transformed cells. Mol Cell Biochem 153: 59-67, 1995
53. Faure R, Vincent M, Dufour M, Shaver A, Posner BI: Arrest at the G2/M transition of the cell cycle by protein tyrosine phosphatase inhibition: Studies on neuronal and glial cell line. J Cell Biochem 59: 389-401, 1995
54. Fantus IG, Tsiani E: Multifunctional actions of vanadium compounds on insulin signaling pathways: Evidence for preferential enhancement of metabolic vs. mitogenic effects. Mol Cell Biochem 182: 109-119, 1998
55. Djordjevic C: Antitumor activity of vanadium compounds. In: H. Sigel and A. Sigel (eds). Biological Systems, Vanadium and Its Role in Life. Marcel Dekker, New York, 1995
56. Cruz TF, Morgan A, Min W: In vitro and in vivo antineoplastic effects of orthovanadate. Mol Cell Biochem 153: 161-166, 1995
57. Liasko R, Kabanos TA, Karkabounas S, Malamas M, Tasiopoulas AJ, Stefanou D, Collery P, Evangelou A: Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo (alpha) pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res 18: 3609-3613, 1998.